Enalapril pharmacology
Pro Research Analysisby 
Searched over 200M research papers for "enalapril pharmacology"
Enalapril Mechanism of Action and Pharmacodynamics
Enalapril is an angiotensin-converting enzyme (ACE) inhibitor used primarily to treat hypertension and heart failure. It is a prodrug that is converted in the liver to its active form, enalaprilat, which inhibits the enzyme responsible for converting angiotensin I to angiotensin II—a peptide that increases blood pressure by causing blood vessels to constrict and stimulating aldosterone secretion. By blocking this conversion, enalapril reduces levels of angiotensin II, leading to decreased vasoconstriction and lower aldosterone secretion, which in turn lowers blood pressure and reduces fluid retention. This mechanism also results in a reduction of peripheral vascular resistance without significant changes in heart rate or cardiac output, and it does not cause sodium retention 1259.
Pharmacokinetics of Enalapril
Enalapril is well absorbed orally, with about 60% absorption and 40% bioavailability as enalaprilat. After administration, enalapril is hydrolyzed in the liver to enalaprilat, which is then excreted unchanged by the kidneys. The active metabolite has a long half-life, allowing for once- or twice-daily dosing. The antihypertensive effect is dose-dependent up to 10 mg, with no further increase at higher doses. Enalaprilat’s functional half-life is about 11 hours, but this can be prolonged in patients with reduced renal function, necessitating dose adjustments in these populations 1256+1 MORE.
Clinical Effects and Therapeutic Use
Enalapril effectively lowers blood pressure in patients with essential and renovascular hypertension and is also beneficial in heart failure by reducing both preload and afterload, improving cardiac performance and clinical status over the long term. It is often used alone or in combination with other antihypertensive agents such as hydrochlorothiazide, which can enhance its effects and help mitigate diuretic-induced hypokalemia. Enalapril does not cause bradycardia, a side effect seen with beta-blockers, and is generally well tolerated with few serious adverse effects 25910.
Pediatric Pharmacology and Dosing Considerations
The pharmacokinetics and safety profile of enalapril in children differ from adults, and data in pediatric populations—especially in young children and those with heart failure—are limited and sometimes conflicting. Recent studies using age-appropriate formulations, such as orodispersible minitablets, have shown that age, weight, serum creatinine, and the severity of heart failure (as measured by the Ross score) are important factors in determining the appropriate dose. Younger children, particularly those under 20 days old, may have higher exposure to enalaprilat, indicating the need for careful dose adjustment and monitoring in this group 4678.
Additional Pharmacological Effects
Beyond its cardiovascular benefits, enalapril has demonstrated anti-arthritic and immunosuppressive properties in experimental models. It appears to exert these effects by targeting inflammatory pathways and molecules such as TNF, MMP-9, and caspase 3, and by stabilizing cell membranes and reducing protein denaturation. These findings suggest potential broader therapeutic applications for enalapril, although more research is needed to confirm these effects in clinical practice .
Drug Interactions and Safety
Enalapril is generally safe, with uncommon and mild side effects. The main known drug interaction is with propranolol, which can reduce enalapril’s bioavailability by about one-third. When used with thiazide diuretics, enalapril can help prevent hypokalemia. Careful monitoring and dose titration are recommended in patients at risk for hypotension or renal impairment, especially in those with renovascular hypertension or who are hypovolemic 125.
Conclusion
Enalapril is a well-established ACE inhibitor with proven efficacy in lowering blood pressure and improving outcomes in heart failure. Its pharmacological profile is characterized by a long-acting active metabolite, renal excretion, and a favorable safety profile. Special consideration is needed for pediatric dosing and in patients with renal impairment. Ongoing research continues to explore its broader therapeutic potential and optimal use in diverse patient populations.
Sources and full results
Most relevant research papers on this topic